News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
HIV treatment in children
FDA Approves INTELENCE® (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1

Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved INTELENCE® (etravirine) to be administered in combination with other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in treatment-experienced pediatric patients (6 years to less than 18 years old) who are experiencing virologic failure with HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other ARVs.

Published
28 March 2012
From
Janssen press release
Health monitoring in resource-limited settings
When does viral load testing add value in sub-Saharan Africa?

Routine viral load testing did not catch failure of first-line treatment earlier than discretionary viral load testing, but it did reduce the period on failing treatment by

Published
08 March 2012
By
Keith Alcorn
Outcomes and prognosis
Second-line treatment failure most often due to poor adherence in low and middle-income countries

Poor adherence rather than drug resistance appears more likely to be the cause of virological failure among patients on second-line ART in resource-poor settings, according to a systematic

Published
24 February 2012
By
Carole Leach-Lemens
Health monitoring in resource-limited settings
Treatment switches after CD4 count decline reduce risk of death by 75% in Zambia, Malawi

Mortality was reduced by about 75% among adults experiencing immunological failure according to the World Health Organization (WHO) criteria who switched to a second-line regimen compared to those

Published
09 December 2011
By
Carole Leach-Lemens
New and experimental HIV treatments
Switching from efavirenz to rilpivirine single tablet is safe and effective

People with undetectable viral load who switched from the efavirenz-containing Atripla single tablet regimen to the new rilpivirine-containing Eviplera (Complera in the United States) coformulation maintained full viral suppression,

Published
18 October 2011
By
Liz Highleyman
Changing treatment
Switching to once-daily etravirine a safe and effective option for individuals taking suppressive protease inhibitor therapy

Patients taking a virologically suppressive HIV treatment combination can safely switch from a protease inhibitor to the new NNRTI etravirine, according to interim results from a small

Published
20 September 2011
By
Michael Carter
Changing treatment
A fifth of patients discontinue Atripla within a year, CNS side-effects the main reason

A fifth of patients who start antiretroviral therapy with Atripla switch to an alternative regimen within a year, according to UK data presented to the 51st

Published
19 September 2011
By
Michael Carter
Health monitoring in resource-limited settings
Viral load monitoring of ART patients linked to lower death rate on treatment in southern Africa

After three years on ART patients enrolled in four scale-up programmes with routine viral load monitoring in South Africa had a fifty percent lower death rate than patients

Published
14 July 2011
By
Carole Leach-Lemens
Health monitoring
Confirmatory viral load reduces HIV treatment switches fourfold in 6-country African study

Targeted viral load testing to confirm treatment failure reduced unnecessary treatment regimen switches four-fold compared to clinical-immunological criteria alone (viral load <1000 copies/ml 12.4% and 46.9%, p<0.001, respectively)

Published
06 July 2011
By
Carole Leach-Lemens
Pharmaceutical industry
Gilead inks one combo HIV drug pact as it explores new ties with J&J -

Under a new pact Gilead will combine its new boosting agent cobicistat with J&J's Prezista, a protease inhibitor. The companies also outlined ongoing talks on a separate pact  on the development and commercialization of a future single-tablet regimen combining Prezista with Gilead's Emtriva, its experimental GS 7340 and cobicistat. Gilead would be responsible for the development and commercialization of the new STR on a worldwide basis.

Published
28 June 2011
From
FierceBiotech
← Prev12345...21Next →

Filter by country